TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Purchased by Great Point Partners LLC

Great Point Partners LLC raised its stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 8.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,016,375 shares of the company’s stock after acquiring an additional 75,544 shares during the period. TScan Therapeutics accounts for approximately 1.5% of Great Point Partners LLC’s portfolio, making the stock its 23rd largest position. Great Point Partners LLC owned approximately 1.92% of TScan Therapeutics worth $5,062,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in TCRX. Dimensional Fund Advisors LP acquired a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $70,000. The Manufacturers Life Insurance Company acquired a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $90,000. SG Americas Securities LLC purchased a new position in shares of TScan Therapeutics during the third quarter worth approximately $78,000. Cornercap Investment Counsel Inc. acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at $134,000. Finally, Rhumbline Advisers purchased a new position in TScan Therapeutics during the 2nd quarter worth $274,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

Insider Buying and Selling

In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were purchased at an average cost of $5.29 per share, with a total value of $26,450.00. Following the purchase, the director now owns 45,000 shares in the company, valued at approximately $238,050. The trade was a 12.50 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.76% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TCRX has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a report on Tuesday, November 12th. Finally, Wedbush reissued an “outperform” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Price Performance

TScan Therapeutics stock opened at $4.64 on Wednesday. The company has a market cap of $247.64 million, a P/E ratio of -4.38 and a beta of 0.79. TScan Therapeutics, Inc. has a one year low of $3.92 and a one year high of $9.69. The business has a fifty day moving average of $5.12 and a two-hundred day moving average of $6.28. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. As a group, analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.